Protein Summary
Disrupts insulin signaling by binding directly to Akt kinases and blocking their activation. May bind directly to and mask the 'Thr-308' phosphorylation site in AKT1. Binds to ATF4 and inhibits its transcriptional activation activity. Interacts with the NF-kappa-B transactivator p65 RELA and inhibits its phosphorylation and thus its transcriptional activation activity. Interacts with MAPK kinases and regulates activation of MAP kinases. May play a role in programmed neuronal cell death but does not appear to affect non-neuronal cells. Does not display kinase activity. Inhibits the transcriptional activity of DDIT3/CHOP and is involved in DDIT3/CHOP-dependent cell death during ER stress. Can inhibit APOBEC3A editing of nuclear DNA. The protein encoded by this gene is a putative protein kinase that is induced by the transcription factor NF-kappaB. The encoded protein is a negative regulator of NF-kappaB and can also sensitize cells to TNF- and TRAIL-induced apoptosis. In addition, this p ...more
- ENST00000217233
- ENSP00000217233
- ENSG00000101255
- C20orf97
- NIPK
- SKIP3
- TRB3
- NIPK
- SINK
- TRB3
- SKIP3
- C20orf97
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
molecular function | 1 | ||
biological process | 0.99 | ||
gene perturbation | 0.99 | ||
small molecule perturbation | 0.99 | ||
PubMedID | 0.93 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 187.51 (req: < 5)
Gene RIFs: 120 (req: <= 3)
Antibodies: 525 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 187.51 (req: >= 5)
Gene RIFs: 120 (req: > 3)
Antibodies: 525 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 23
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0